Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 168,677

Document Document Title
WO/2018/168879A1
[Problem] To provide a composition having an estrogen-like action which comprises a hot water extract of Sparassis crispa mycelia.  
WO/2018/168768A1
The purpose of the present invention is to provide a biomarker for obstructive pulmonary diseases such as bronchial asthma, and a method for using the biomarker. The present invention involves extracellular-vesicle protein groups (A) thr...  
WO/2018/168579A1
Disclosed is a genome stability enhancer that contains, as an active ingredient, at least one selected from the group consisting of enzymatically degraded royal jelly, gnetum or an extract thereof, and gnetin C.  
WO/2018/169090A1
Provided is an agent for suppressing or reducing photoreception sensitivity containing a substance that inhibits or suppresses ubiquitination, such as an agent for suppressing or reducing photoreception sensitivity that protects the reti...  
WO/2018/168818A1
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them an...  
WO/2018/167103A1
The present invention relates to a combination product and its use in therapy.  
WO/2018/168407A1
Provided are: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway through futalosine or a futalosine derivative, said composition comprising as an active ingredient a fatty acid which carries 18 ...  
WO/2018/167162A1
The invention relates to a therapeutic regimen for the parenteral administration of melatonin-based formulations to neonates affected by a brain injury disease due to birth asphyxia.  
WO/2018/168333A1
[Problem] To provide a novel medicine that is capable of promoting cholesterol metabolism to thereby treat, ameliorate or prevent various symptoms associated with increase in blood cholesterol level. [Solution] The present inventors newl...  
WO/2018/169063A1
Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog...  
WO/2018/168898A1
The present invention pertains to a therapeutic agent against diseases involving Nav 1.7, specifically, diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme p...  
WO/2018/168829A1
A production method for helper T cells, the method including: (i) a step in which T cells that have been induced from pluripotent stem cells and have had the CD4 gene or the product of said gene introduced thereinto are cultured in a cul...  
WO/2018/164191A1
The present invention provides a substituted pyrrolidine compound having orexin receptor type 2 agonist activity. A compound represented by the formula (in the formula, each symbol is as described in the specification) or a salt thereof ...  
WO/2018/164116A1
A liposome that contains a mycolic acid and a sterol compound.  
WO/2018/164254A1
The present invention provides a composition for promoting an increase in the level of brain-derived neurotrophic factor (BDNF) in the body, especially in the muscles. This composition for promoting an increase in the level of BDNF in th...  
WO/2018/164027A1
Provided is a drug that can effectively inhibit histone-mediated cytotoxicity. The drug for inhibiting histone-mediated cytotoxicity is characterized by having antithrombin III as an active ingredient. The antithrombin III is preferably ...  
WO/2018/164192A1
The present invention provides a substituted pyrrolidine compound having orexin-2 receptor agonistic activity. A compound represented by formula (I) (wherein the symbols are as described in the description) or a salt thereof has orexin-2...  
WO/2018/163119A1
The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.  
WO/2018/164113A1
A model closely resembling human high myopia can be constructed by fitting a juvenile mouse with a minus lens capable of angle and width adjustment in correspondence to the growth of the mouse, and with a protector. Analysis with this mo...  
WO/2018/159522A1
Provided is a food composition for preventing or alleviating metabolic syndrome, the food composition containing, as active ingredients, a 67 kDa laminine receptor (67LR) agonist and a sulfur-containing compound found from an allium plan...  
WO/2018/159845A1
The purpose of the present invention is to provide a novel therapeutic or preventive agent for human T-cell leukemia virus-1-associated myelopathy (HAM), characterized by containing an anti-human CC-chemokine receptor 4 (CCR4) antibody o...  
WO/2018/160154A1
The invention relates to a lotion composed of individuals or combinations of compounds selected from a group consisting of acid, iron oxide, water, oil, surfactant for treatment of diseases arising from iron deficiency.  
WO/2018/161077A1
Methods to interrogate and modulate gut barrier integrity are provided. Methods for treating leaky gut barrier are also provided. Methods for early detection of diseases associated with inflammatory disorders. Methods to rapidly assess t...  
WO/2018/159808A1
The present invention provides: an antibody-drug conjugate of an anti-IL-7R antibody; and a pharmaceutical composition for treating cancer or inflammation and containing an antibody-drug conjugate of an anti-IL-7R antibody and a cytotoxi...  
WO/2018/158249A1
The present invention relates to a highly room temperature stable drug dosage forms comprising a Carbamoyl Phosphate Synthetase 1 (CPS 1) activator susceptible to degradation, notably moisture-induced; and at least one pharmaceutically a...  
WO/2018/160775A1
Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant admi...  
WO/2018/159734A1
The present invention addresses the problem of providing a production method for crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nic otinic acid. A compound represented by general formula [3] (wherein R1 represents a...  
WO/2018/159705A1
As novel use of an Euglena extract, provided are: a novel adipocyte differentiation inhibitor; a PPARγ expression inhibitor; a C/EBPα expression inhibitor; a food composition for inhibiting adipocyte differentiation; and a cosmetic com...  
WO/2018/159632A1
[Problem] To provide a material for improving endometriosis with which it is possible to improve endometriosis and which is a material in which aglycone isoflavones are utilized, and a method for producing the material. [Solution] Produc...  
WO/2018/159613A1
Provided is a cancer treatment method that uses a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. An antitumor agent that combines: a pyrazolo[3,4-d]pyrimidine compound represented by general formula (I) (in which X, Y, Z1, Z2, Z3,...  
WO/2018/159432A1
The purpose of the present invention is to provide a mesenchymal stem cell that is highly safe when used as a medicinal product. The present invention is a mesenchymal stem cell characterized in that the tissue factor (TF) is expressed a...  
WO/2018/159650A1
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...  
WO/2018/160055A1
The present disclosure provides a method for preventing or treating an autism spectrum disorder in a subject in need thereof. The method includes administering to the subject a composition containing a therapeutically effective amount of...  
WO/2018/159546A1
The present invention addresses the problem of providing an exceptional GLP-1 secretagogue that is a component derived from milk, a composition for promoting GLP-1 secretion, and a food/beverage or drug containing the same. Any selected ...  
WO/2018/159852A1
The purpose of the present invention is to provide a curcumin-containing solid composition which can be used as a composition for treatment or prevention of disorders or symptoms in which intracellular absorption of curcumin is beneficia...  
WO/2018/155525A1
The purpose of the present invention is to provide a novel anti-inflammatory agent. Provided is an anti-inflammatory agent including a liver hydrolysate as an active ingredient.  
WO/2018/157000A1
A trigger-responsive dominant negative signaling polypeptide disclosed herein can include a modulating domain and a dominant negative signaling moiety. A modulating domain can be characterized by an ability to adopt a first state and a s...  
WO/2018/155686A1
The purpose of the present invention is to provide a leptin secretion promoter that is capable of easily promoting the secretion of leptin. A catechin compound having a specific structure [i.e., a catechin compound represented by general...  
WO/2018/155450A1
The purpose of the present invention is to provide an antisense oligonucleic acid having reduced hepatotoxicity. This antisense oligonucleic acid is characterized by: having a base length of 7-30 nt; nucleic acid residues, each of which ...  
WO/2018/156459A1
A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or...  
WO/2018/154517A1
This invention relates ιο methods and compositions, in a combination therapy, for treatment of neoplastic disease, including tenors and cancer, wherein an immunocytokine arid a small molecule drug conjugate which comprises a moiety cap...  
WO/2018/155451A1
The purpose of the present invention is to provide: a nucleic acid compound represented by formula (I) or formula (II), said nucleic acid compound hardly forming a non-Watson-Crick base pair; and an oligonucleotide which comprises the nu...  
WO/2018/155398A1
The present invention addresses the problem of finding a novel medicine that has an excellent tryptophanase inhibitory effect, that suppresses deterioration of renal functions by reducing indoxyl sulfate production in blood, and that con...  
WO/2018/149925A1
The present invention discloses compositions comprising compounds according to Formula I wherein R1, R2, and Cy are as defined herein, and a second compound having a JAK inhibiting activity. The present invention relates to composition, ...  
WO/2018/148797A1
The present invention relates to the treatment of equine animals presenting with an inflammatory condition and/or symptoms associated with inflammation and/or which have a condition which could lead to an inflammatory disorder. Formulati...  
WO/2018/151245A1
The present invention provides an interleukin-23 production promoting composition that enables the elimination of cumbersome procedures such as encapsulation and flavor alteration. The interleukin-23 production promoting composition acco...  
WO/2018/151326A1
Provided is a pharmaceutical composition for a genetic disease associated with splicing abnormalities. A pharmaceutical composition for the prevention, amelioration, progression prevention and/or treatment of a genetic disease associated...  
WO/2018/151046A1
The purpose of the present invention is to provide a novel treatment agent for pulmonary fibrosis for which there is currently no effective drug therapy established. The present invention is a pulmonary fibrosis treatment agent containin...  
WO/2018/151225A1
The muscle differentiation promoter according to the present invention includes oligo DNA having activity to promote muscle differentiation by being applied to cells or to an individual. The oligo DNA preferably includes a core base sequ...  
WO/2018/152339A1
In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the br...  

Matches 1 - 50 out of 168,677